All In Biotech

Free tool

FAERS Monitor: Rivfloza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215842 or its brand name (Rivfloza, Nedosiran Sodium). Reports on generic versions are filed under their own applications.

Reports

12

Serious

8

67% of reports

Hospitalization

3

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urine oxalate increased3
  • inappropriate schedule of product administration2
  • rash2
  • abdominal pain1
  • amenorrhoea1
  • bone pain1
  • death1
  • dehydration1
  • diabetes mellitus1
  • drug ineffective1
  • febrile infection1
  • haemoglobin increased1
  • hyperoxalaemia1
  • hyperoxaluria1
  • influenza1

Reports by year received

View as table
YearReports
20243
20259

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,147 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperoxalaemia1159501.122301.236,551
urine oxalate increasedSignal375193.427452.4150,211
hyperoxaluria110260.31561.72,549
febrile infection11491.9228.2372
haemoglobin increased1384.358.895
amenorrhoea199.915.324
bone pain129.94.67
diabetes mellitus123.03.55
inappropriate schedule of product administration219.55.519
influenza115.72.43
dehydration113.12.02
rash28.02.36
abdominal pain17.51.21
death12.00.30
drug ineffective11.30.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.